Replies to post #511 on Food Innovation

[gfp927z]

Reportedly, the 'all cause' death rate jumped ~ 40% for two quarters last Fall/Winter, which was unprecedented. 'All cause death' is a statistic followed closely by the life insurance industry, and they were reportedly freaked out about it. Funeral directors and embalmers were also reportedly alarmed by "weird, freakishly large blood clots clogging veins in vaccinated bodies" -


https://investorshub.advfn.com/boards/read_msg.aspx?message_id=167944156


Even without the scientific and media blackout of this type of info, it would be very difficult to figure out how much of the observed effects are from the vaccines, and how much from Covid itself. People are being exposed and re-exposed to the live virus daily, and as a virus, Covid can presumably live inside the body for months, years, maybe forever. In contrast, the spike protein produced by the vaccines is present in the body for only a short time. The vaccines do also have the nano-lipid component, which might have its own potential for toxicity.

So lots of unknowns, and plenty of reasons to be wary of both the virus and the vaccines. The virus most likely came out of a lab, and the mRNA vaccines are new and experimental, and without the usual long term safety studies. Add to this the fact that many/most people have come to distrust both big pharma and big government, for good reason. Both lie routinely, so In legal speak - 'falsus uno, falsus omnibus'.




---

[gfp927z]

Looks like tax selling could be likely for RIBT this year. The chart looks ominous, so will see if 1.00 holds. I see the $3 mil financing in Sept had warrants priced at 0.65, so that might be a potential downside target to watch since anything above that makes it profitable to exercise the warrant and sell the resulting shares. Also, looks like the warrants have an 'adjustment' feature, by which they can be re-priced lower after the 1st and 2nd anniversary. That isn't a factor yet, but can encourage manipulation later as the anniversary date approaches next year.

In my small cap biotech investing days, we used to dread these desperation type financings since once a company is running on fumes, the financing ghouls will take full advantage. Hopefully the company will have some positive developments next year to turn things around, but looks like RIBT is clearly in the 'Danger Will Robinson' category..



https://irdirect.net/prviewer/release_only/id/4856093


>>> Under the securities purchase agreement, the Investor has agreed to purchase (i) 2,307,500 shares of the Company's Common Stock at a purchase price of $0.65 per share, (ii) warrants to purchase 2,307,885 shares of Common Stock, exercisable for a period of five years following the date of issuance with an exercise price of $0.65 per share, $0.6499 per share of which will be prefunded, and (iii) warrants to purchase 2,307,693 shares of common stock exercisable for a period of five years following the date of issuance with an exercise price of $1.00 per share, which exercise price will be subject to adjustment on the first and second anniversaries of issuance if 110% of the 5-day volume weighted average price of the Company's Common Stock is less than the then-current exercise price. The closing is expected to occur on September 13, 2021, subject to customary conditions. Until the second anniversary of the closing of this offering, the Investor will have the right to participate for up to 45% of the securities offer by the Company in future offerings, subject to certain exceptions, and the Company has agreed to suspend its sale of securities under it's At The Market (ATM) equity issuance program.

<<<



---

[gfp927z]

Condolences on RIBT, but I wonder if it might be approaching a near term bottom (?)

Since the warrants from the Sept financing are exercisable at 0.65, it is profitable for holders to exercise and sell the resulting shares at anything above that level. So 0.65 might represent a 'floor', at least when it comes to selling pressure from the warrant side. Regular tax loss selling is another source of the current price drop, and that should end in several weeks.

However, looking at the prospects for a January bounce, while the tax selling should be gone at year's end, the 0.65 warrant aspect will still be there as long as the 2.3 mil of warrants are around. There is also a 2nd tranche of 2.3 mil warrants priced at $1 (which can be re-priced lower at a later date), so these could represent an upside barrier at $1 for the share price.

All in all it's a messy picture once these crappy financings enter the picture. You see this a lot with small bio stocks that do desperation financings, as the chronic lack of earnings leads to a 'circling the drain' vortex -


https://irdirect.net/prviewer/release_only/id/4856093


>>> Under the securities purchase agreement, the Investor has agreed to purchase (i) 2,307,500 shares of the Company's Common Stock at a purchase price of $0.65 per share, (ii) warrants to purchase 2,307,885 shares of Common Stock, exercisable for a period of five years following the date of issuance with an exercise price of $0.65 per share, $0.6499 per share of which will be prefunded, and (iii) warrants to purchase 2,307,693 shares of common stock exercisable for a period of five years following the date of issuance with an exercise price of $1.00 per share, which exercise price will be subject to adjustment on the first and second anniversaries of issuance if 110% of the 5-day volume weighted average price of the Company's Common Stock is less than the then-current exercise price. The closing is expected to occur on September 13, 2021, subject to customary conditions. Until the second anniversary of the closing of this offering, the Investor will have the right to participate for up to 45% of the securities offer by the Company in future offerings, subject to certain exceptions, and the Company has agreed to suspend its sale of securities under it's At The Market (ATM) equity issuance program.

<<<




---